TrialSignal transduction and targeted therapy2025

First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trial.

Yuankai Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.